Skip to main content
Fig. 6 | European Journal of Medical Research

Fig. 6

From: EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms

Fig. 6

Immune responses of EXTL3 gene to immunotherapies: A distribution of EXTL3 in pan-cancer immune subtypes; B TIDE score in different EXTL3 subgroups; C T cell dysfunction score in different EXTL3 subgroups; D immune exclusion score in different EXTL3 subgroups; E immune responses of EXTL3 to anti-PD-L1 treatment atezolizumab in the IMvigor210 cohort. **P < 0.01;***P < 0.001

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us